Avia Logo

Compare Products


Jump to:
Categories
Solutions
Description
Compatibility Level
Clients
Use cases
EHR integrations
Client types
Differentiators
Keywords
Media
Company details
Jump to:
Categories
Solutions
Description
Compatibility Level
Clients
Use cases
EHR integrations
Client types
Differentiators
Keywords
Media
Company details
Upstream Bio
Upstream Bio

0 review

Categories

Solutions

Description

Product Description:
Upstream Bio develops a clinical-stage monoclonal antibody that inhibits the TSLP receptor. Its program aims to be positioned upstream in the inflammatory cascade with the potential to impact multiple diseases, including asthma. Upstream Bio serves clients operating in the healthcare sector. It was founded in 2021 and is based in Waltham, Massachusetts.
About Upstream Bio:
Upstream Bio develops a clinical-stage monoclonal antibody that inhibits the TSLP receptor. Its program aims to be positioned upstream in the inflammatory cascade with the potential to impact multiple diseases, including asthma. Upstream Bio serves clients operating in the healthcare sector. It was founded in 2021 and is based in Waltham, Massachusetts.
Product Description:
Intrommune Therapeutics is a clinical stage biotechnology company that is developing convenient, safe and effective options for individuals suffering with food allergies. Intrommune’s therapies are delivered through a platform that integrates simply into a person’s daily routine to enable them and their loved ones to live their lives without fear. The Company’s Oral Mucosal Immunotherapy (OMIT) platform is based on the well-accepted principles of immunotherapy. OMIT utilizes a specially formulated toothpaste that optimizes exposure of allergenic proteins to a patient’s immune system, while cleaning their teeth. The initial product in development is INT301 for the treatment of peanut allergy. The lack of treatments makes food allergies an area of tremendous unmet need. The FDA has only approved one product for any food allergy, a peanut allergy immunotherapy that requires you to ingest peanut protein. As desperate as patients are for solutions, due to significant adverse events and difficulty in administration, only 1 in 10 eligible patients are willing to ingest peanut protein. Nonetheless, the company was recently acquired for $2.6 billion. With minimal options, patients and caregivers must resort to attempting to avoid allergy-triggering foods in the often-futile hope of preventing severe allergic reactions. In short, patients, parents, providers and payors are all seeking a safe, efficacious, and easy to administer product such as INT301. Intrommune Therapeutics’ Phase 1b study in individuals with peanut allergy is on-going and is on a development timeline with significant near-term value inflection events expected over the next 12 months
About Intrommune Therapeutics:
Intrommune Therapeutics is a clinical stage biotechnology company that is developing convenient, safe and effective options for individuals suffering with food allergies. Intrommune’s therapies are delivered through a platform that integrates simply into a person’s daily routine to enable them and their loved ones to live their lives without fear. The Company’s Oral Mucosal Immunotherapy (OMIT) platform is based on the well-accepted principles of immunotherapy. OMIT utilizes a specially formulated toothpaste that optimizes exposure of allergenic proteins to a patient’s immune system, while cleaning their teeth. The initial product in development is INT301 for the treatment of peanut allergy. The lack of treatments makes food allergies an area of tremendous unmet need. The FDA has only approved one product for any food allergy, a peanut allergy immunotherapy that requires you to ingest peanut protein. As desperate as patients are for solutions, due to significant adverse events and difficulty in administration, only 1 in 10 eligible patients are willing to ingest peanut protein. Nonetheless, the company was recently acquired for $2.6 billion. With minimal options, patients and caregivers must resort to attempting to avoid allergy-triggering foods in the often-futile hope of preventing severe allergic reactions. In short, patients, parents, providers and payors are all seeking a safe, efficacious, and easy to administer product such as INT301. Intrommune Therapeutics’ Phase 1b study in individuals with peanut allergy is on-going and is on a development timeline with significant near-term value inflection events expected over the next 12 months

Compatibility level

Select which hospital or health system you work at and see a personalized compatibility level.

Clients

Select which hospital or health system you work at and see the client list

Use Cases

Description:

None provided

Pediatric use cases:

None provided

Users:

None provided

Description:

None provided

Pediatric use cases:

None provided

Users:

None provided

EHR Integrations

Integrations:

None provided

EMR Integration & Relevant Hardware:

None provided

EMRs Supported:

None provided

Hardware Compatibility:

None provided

Integrations:

None provided

EMR Integration & Relevant Hardware:

None provided

EMRs Supported:

None provided

Hardware Compatibility:

None provided

Client Types

None provided
None provided

Differentiators

Differentiators vs EHR Functionality:

None provided

Differentiators vs Competitors:

None provided

Differentiators vs EHR Functionality:

None provided

Differentiators vs Competitors:

None provided

Keywords

Images

No images provided

No images provided

Videos

No videos provided

No videos provided

Downloads

No content provided

No content provided

Alternatives

Company Details

team illustration
Share your product comparison with your collegues.

Need help narrowing down products?

Add more criteria to see your compatibility level for every vendor. It only takes a few minutes, just create a free account to get started.
back to top